Geneos Wealth Management’s Altimmune ALT Stock Holding History

Geneos Wealth Management’s Portfolio ALT Stock Details ALT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$30.4K	Hold	10,000	–	–	﹤0.01%	1655
2026 Q1	$30.8K	Hold	10,000	–	–	﹤0.01%	1615
2025 Q4	$36.1K	Hold	10,000	–	–	﹤0.01%	1516
2025 Q3	$37.7K	Hold	10,000	–	–	﹤0.01%	1484
2025 Q2	$38.7K	Hold	10,000	–	–	﹤0.01%	1712
2025 Q1	$50K	Buy	+10,000	New	+$63.3K	﹤0.01%	1472
2020 Q4	–	Sell	-1,000	Closed	-$12K	–	2883
2020 Q3	$12K	Buy	+1,000	New	+$20K	﹤0.01%	1871

Other funds holding ALT

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

TCM

TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return

RCM

RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Geneos Wealth Management's ALT Position: Q2 2026 in Review

Geneos Wealth Management held its Altimmune (ALT) position steady in Q2 2026 at 10,000 shares worth $30.4K. The position accounts for ﹤0.01% of the portfolio, ranked #1655.

Geneos Wealth Management first reported a position in ALT in Q3 2020 and has held it in 7 quarters since. The position peaked at $50K in Q1 2025. 210 funds tracked by Wall St. Rank hold ALT as of Q2 2026.

Geneos Wealth Management held 10,000 shares of Altimmune worth $30.4K as of Q2 2026.
Geneos Wealth Management left its Altimmune share count unchanged in Q2 2026.
Altimmune made up ﹤0.01% of Geneos Wealth Management's portfolio in Q2 2026, its #1655 holding.
Geneos Wealth Management first reported a position in Altimmune in Q3 2020 and has held it in 7 quarters since.
Geneos Wealth Management's Altimmune position peaked at $50K in Q1 2025.
210 funds tracked by Wall St. Rank held Altimmune as of Q2 2026.

Based on Geneos Wealth Management's 13F filing for Q2 2026, filed 6 Aug 2026.